University Hospital, Hradec Králové, Czech Republic.
Adv Ther. 2012 Jan;29(1):41-52. doi: 10.1007/s12325-011-0090-5. Epub 2012 Jan 3.
Intanza(®)/IDflu(®) (Sanofi Pasteur SA, Lyon, France), a split-virion, trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available in adults 18-59 years of age (9 μg) and ≥60 years of age (15 μg) as of the 2010/2011 northern hemisphere influenza season.
This study assessed the acceptability of intradermal vaccination with Intanza/IDflu in routine clinical practice in adult vaccinees and their vaccine prescribers. Vaccine prescribers and adults who had elected to be vaccinated with Intanza/IDflu during the 2010/2011 northern hemisphere influenza season were recruited to complete surveys about their opinions of influenza vaccination and their acceptance of the intradermal vaccination. Czech subjects 18-59 years of age were vaccinated with the 9 μg formulation and those ≥60 years of age with the 15 μg formulation of Intanza/IDflu. All Turkish subjects were vaccinated with the 9 μg formulation, as Intanza/IDflu 15 μg was not available in Turkey at the time the survey was conducted.
One thousand and twelve vaccinees and 28 vaccine prescribers in the Czech Republic, and 249 vaccinees and 15 vaccine prescribers in Turkey completed questionnaires. Overall, 96.1% of vaccinees were satisfied or very satisfied with Intanza/IDflu. The main reason for satisfaction was that the injection was considered minimally painful. Most (93.9%) vaccinees reported that they would prefer to receive the same vaccination next year. Furthermore, 95.3% of vaccine prescribers were satisfied or very satisfied with the intradermal vaccine, and 82.6% preferred intradermal over intramuscular vaccination.
Intradermal vaccination for seasonal influenza using Intanza/IDflu is well accepted by adult vaccinees and vaccine prescribers. By providing an additional, well-accepted method, Intanza/IDflu might help increase seasonal influenza vaccination rates in adults.
自 2010/2011 年北半球流感季节起，用于皮内注射的含分裂病毒的三价流感疫苗 Intanza（®）/IDflu（®）（赛诺菲巴斯德公司，法国里昂）可用于 18-59 岁（9μg）和≥60 岁（15μg）成年人。
本研究评估了在常规临床实践中，Intanza/IDflu 皮内接种在成年疫苗接种者及其疫苗接种者中的可接受性。在 2010/2011 年北半球流感季节选择接种 Intanza/IDflu 的疫苗接种者和疫苗接种者被招募来完成关于他们对流感疫苗接种的看法和对皮内接种的接受程度的调查。捷克的 18-59 岁年龄组接种 9μg 制剂，≥60 岁年龄组接种 15μg 制剂的 Intanza/IDflu。所有土耳其受试者均接种 9μg 制剂，因为在进行调查时，土耳其没有供应 Intanza/IDflu 15μg 制剂。
在捷克共和国，1012 名疫苗接种者和 28 名疫苗接种者以及 249 名疫苗接种者和 15 名疫苗接种者完成了调查问卷。总体而言，96.1%的疫苗接种者对 Intanza/IDflu 满意或非常满意。满意的主要原因是注射疼痛感极小。大多数（93.9%）疫苗接种者表示，他们明年更愿意接种相同的疫苗。此外，95.3%的疫苗接种者对皮内疫苗满意或非常满意，82.6%的人更喜欢皮内疫苗而不是肌内疫苗。
使用 Intanza/IDflu 进行季节性流感的皮内接种受到成年疫苗接种者和疫苗接种者的广泛认可。通过提供另一种可接受的方法，Intanza/IDflu 可能有助于提高成年人季节性流感疫苗接种率。
